Protective Ileostomy Versus Protective Colostomy in Anterior Rectal Resection
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Oct 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two types of temporary surgical openings called stomas: loop ileostomy and loop colostomy. Both of these procedures can be used to help protect the intestines after a surgery called anterior rectal resection, which is done to remove part of the rectum due to cancer. The goal of the trial is to find out which type of stoma has fewer problems or complications in the first 60 days after surgery.
To participate in this trial, patients need to be between the ages of 18 and 74 and scheduled for anterior rectal resection with the plan to create a protective stoma. However, those who already have a stoma, have certain anatomical issues, or cannot cooperate due to other medical reasons will not be eligible. If you join the trial, you will be randomly assigned to receive either a loop ileostomy or a loop colostomy during your surgery. The research aims to provide more information on the best option for patients undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Patients undergoing anterior resection (resection of the rectum and colorectal or coloanal anastomosis) due to a rectal tumour and a protective stoma is planned.
- • The exclusion criteria are: (1) patient already having a stoma (or another stoma made during surgery), (2) technical inability to create ileo- or colostomy (e.g. previous bowel resection, anatomical factors), (3) age \<18 years, (4) inadequate ability to co-operate.
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Tampere, , Finland
Turku, , Finland
Patients applied
Trial Officials
Ville Sallinen, MD, PhD
Principal Investigator
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported